Perez de Isla, LeopoldoAlonso, RodrigoWatts, Gerald F.Mata, NelvaSaltijeral Cerezo, AdrianaMuniz, OvidioFuentes, FranciscoLuis Diaz-Diaz, Josede Andres, RaimundoZambon, DanielRubio-Marin, PatriciaBarba-Romero, Miguel A.Saenz, PedroSanchez Munoz-Torrero, Juan F.Martinez-Faedo, CeferinoMiramontes-Gonzalez, Jose P.Badimon, LinaMata, PedroSAFEHEART Investigators2023-02-122023-02-122016-03-220735-1097http://hdl.handle.net/10668/18806BACKGROUND Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information.OBJECTIVES We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry.METHODS The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT).RESULTS The study recruited 4,132 individuals (3,745 of whom were >= 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target = 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment targetencardiovascular diseaseLDL-receptor mutationslipid-lowering therapylow-density lipoprotein cholesterolGuidanceManagementEzetimibeMortalityEfficacyTherapyDiseaseCohortRiskCareresearch article10.1016/j.jacc.2016.01.0081558-3597371881400003